Tillotts Pharma AG announces that DIFICLIRTM (fidaxomicin) is recommended for the treatment of Clostridioides difficile infection (CDI) by ESCMID
Retrieved on:
Wednesday, December 8, 2021
Health, Infectious Diseases, Clinical Trials, Research, Pharmaceutical, Science, Medical microbiology, Disease, CDI, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, News, Risk factor, ESCMID, Recurrence, Goldenberg, Dis, Clostridioides difficile infection, Microbiota, Infection, PMID, Acquisition, Plasma protein binding, Clostridioides, Meta-analysis, ECDC, IDSA, Patient, IBD, Consultant, Mortality, OTC, Human, Tesco international operations, Clostridium difficile, Systematic review, Vancomycin, European Centre for Disease Prevention and Control, Lancet, University, Tablet, Guideline, Society, Wes Tillott, Fidaxomicin, CDAD, Health care, MD, Adult, RNA, Clinical trial, Trial of the century, Vaccine, Pharmaceutical industry, DIFICLIRTM, Tillotts, Zeria, DIFICLIRTM, TILLOTTS, ZERIA
Despite the endemic nature of C. difficile in many healthcare settings, sustained clinical cure and prevention of recurrence are achievable treatment goals for CDI.
Key Points:
- Despite the endemic nature of C. difficile in many healthcare settings, sustained clinical cure and prevention of recurrence are achievable treatment goals for CDI.
- European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.
- Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
- Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma company with over 300 employees in Switzerland and abroad.